Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Wiersema

Physical Medicine & Rehabilitation Saginaw, MI Doctor of Osteopathy

NPI 1851322549 CMS profile 265268

4701 Towne Centre Rd Ste 102, Saginaw, MI 48604

Open in the dashboard

General payments

$17,019

248 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Wiersema of Saginaw, MI is reported in the CMS Open Payments database as having received $17,019 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,790 51
2024 General $6,432 45
2023 General $1,914 32
2022 General $5,359 31
2021 General $509 29
2020 General $564 31
2019 General $452 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Wiersema
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to David Wiersema were reported at $1,790. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year David Wiersema Physical Medicine & Rehabilitation median Middle half National median
2019 $452 $133 $45–$390 $163
2020 $564 $88 $29–$272 $114
2021 $509 $116 $33–$360 $132
2022 $5,359 $123 $40–$378 $149
2023 $1,914 $131 $43–$396 $160
2024 $6,432 $141 $45–$409 $164
2025 $1,790 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $13,754 85 payments
  2. Neurocrine Biosciences, Inc. $928 36 payments
  3. Allergan Inc. $560 34 payments
  4. Idorsia Pharmaceuticals US Inc $227 11 payments
  5. Eisai Inc. $184 3 payments
  6. Amgen Inc. $182 11 payments
  7. Avanir Pharmaceuticals, Inc. $139 9 payments
  8. Radius Health, Inc. $121 8 payments
  9. Abbott Laboratories $68 3 payments
  10. Pfizer Inc. $65 4 payments
  11. Other $791 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,400 8 payments
  2. Food and Beverage $5,480 232 payments
  3. Travel and Lodging $2,092 5 payments
  4. Gift $33 2 payments
  5. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. BOTOX Neuroscience $12,190 25 payments
  2. QULIPTA $1,002 34 payments
  3. INGREZZA $766 25 payments
  4. BOTOX Botox Therapeutic $574 26 payments
  5. BOTOX Hyperhydrosis $531 33 payments
  6. UBRELVY $442 16 payments
  7. QUVIVIQ $227 11 payments
  8. Dayvigo $184 3 payments
  9. NUEDEXTA $139 9 payments
  10. EVENITY $124 7 payments
  11. Other $1,644 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

171

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$57,337

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

14%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Forteo Teriparatide Brand 11 $49,320
Trintellix Vortioxetine Hydrobromide Brand 13 $6,049
Baclofen Generic 58 $1,187
Gabapentin Generic 24 $323
Oxycodone Hcl Generic 13 $166
Trazodone Hcl Generic 12 $118
Pregabalin Generic 15 $110
Tramadol Hcl Generic 25 $64

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$69,987

Medicare's payments for the services billed

Medicare patients

153

Average age 71

Services billed

5,191

87 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Diabetes 31%
Depression 31%
Ischemic heart disease 29%
COPD 24%
Chronic kidney disease 22%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $5,688
$5,688 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $224
$224 — —
QULIPTA
  • AbbVie, Inc. $202
$202 — —
UBRELVY
  • AbbVie, Inc. $99
$99 — —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record